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C O N F E R E N C E   R E P O R T
In the United States, approximately 12 million to 14 mil-lion units of blood are donated annually.1 These unitstypically are fractionated into some 20 million bloodcomponents, mainly RBCs, platelets, and FFP.2 Alter-
natively, plasma, RBCs, and platelets may be obtained by
apheresis. On average, 3 million to 4 million patients receive
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blood transfusions annually, with overall costs of blood ser-
vices estimated to be 1 percent of health care expenditures.3,4
Although current fractionation procedures are highly
effective, significant numbers of WBCs remain in RBCs and
platelets that are prepared from whole blood.5,6 Evidence
from published clinical studies implicates residual alloge-
neic WBCs in transfused components as a cause of HLA allo-
immunization, platelet refractoriness, CMV transmission,
and febrile nonhemolytic transfusion reactions (FNHTRs).5,7,8
Passenger WBCs have been associated with a number of
other adverse transfusion-related effects, such as
immunomodulation,9-12 and the transmission of prion dis-
eases, such as variant CJD (vCJD).13 However, clinical data
to date are either inconsistent or insufficient to prove any
of the latter associations.
In September 1998, the FDA Blood Products Advisory
Committee unanimously affirmed the following question: “Is
the benefit-to-risk ratio associated with leukoreduction
[WBC reduction] sufficiently great to justify requiring the
ULR [universal leukoreduction] of all non-leukocyte cellu-
lar transfusion components, irrespective of the theoretical
considerations for transfusion-transmitted CJD?” In Janu-
ary 2001, the Advisory Committee on Blood Safety and Avail-
ability of the Department of Health and Human Services
(DHHS) voted to recommend that the FDA implement ULR
in the United States as soon as feasible. Thus, the FDA likely
will begin the process that would ultimately make WBC re-
duction a manufacturing requirement for blood providers,
thereby converting the US blood supply to 100-percent WBC
reduced. However, significant disagreement remains among
transfusion medicine specialists with respect to the scien-
tific and clinical justification for mandated ULR.14
Modern medical practice unquestionably requires an
adequate, reliable blood supply that is made as safe as pos-
sible by using current technologies. To achieve these ends,
the US blood supply is overseen and regulated through a
network of programs that operate at the national level.15 By
these efforts, the US blood supply has never been safer.1 As
may be anticipated, though, the stringent oversight and
manufacturing process regulations that are imposed to en-
sure blood quality and safety are not cost-free; in fact, each
new technology or process has increased costs. It has been
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estimated that ULR will increase the cost of blood services in
the United States by at least $500 million annually.8
Because of the intertwined—and, in some cases, discor-
dant—clinical, safety, availability, and cost issues involved,
blood evokes emotions and controversy that often seem to
pit major stakeholders in the US health care system against
one another. As a consequence, WBC reduction, and in par-
ticular the proposal for ULR, has become controversial. The
University HealthSystem Consortium (UHC), an alliance of
more than 80 academic medical centers, in response to its
members’ concerns, convened an Expert Panel to develop
evidence-based recommendations for the use of WBC re-
duced cellular blood components. This article summarizes
the findings of the UHC Expert Panel.
ORGANIZATION AND PREPARATION OF
THE EXPERT PANEL
A systematic, qualitative review of the clinical literature was
performed to identify published evidence related to the safety,
efficacy, and utility of WBC reduced cellular blood components.
Evidence was obtained through a computer-based search of
the  National Library of Medicine’s MEDLINE reference data-
base (http://www.ncbi.nlm.nih.gov/PubMed/). Fifteen review
articles containing the keywords “leuko- reduced” and “blood”
that were published in English in any field between 1990 and
August 2000 were retrieved. The reference list for each article
was examined to identify reviews missed in the database search.
The “related articles” function of MEDLINE was used to iden-
tify 115 more citations on WBC reduced blood that were
screened for their relevance.
MEDLINE was subsequently searched to identify En-
glish-language reports of original data on WBC reduced blood
(human clinical use only, randomized trials, editorials, let-
ters, comments). A total of 135 citations in this category were
identified for the period between January 1, 1990 and August
1, 2000. The reference list of each article retrieved was ex-
amined to identify original work that had eluded the com-
puter-based search; the “related articles” function of
MEDLINE also was used for this purpose. A bibliography
comprising 173 articles (reviews, meta-analyses, original re-
search, editorials) was compiled for the UHC Expert Panel
before the committee meeting.
A modified grading system was used to categorize the
levels of evidence according to study design,16-18 as summa-
rized in Table 1. Data from randomized controlled trials were
considered relatively reliable evidence of the clinical effec-
tiveness of WBC reduced blood. Uncontrolled open series,
cohort studies, retrospective analyses, and case reports were
considered less reliable sources of data. An evidence grade
of Type IV was reserved for situations in which panel mem-
bers felt a decision on use could not be determined because
of insufficient or conflicting evidence. In any case, the evi-
dence grading system does not reflect the strength of rec-
ommendation, but instead measures the strength of the avail-
able data.
The composition and conduct of the UHC Expert Panel
were determined by using as a conceptual framework ele-
ments of the NIH Consensus Development Program.19 A Re-
quest for Consultants was sent directly to each UHC mem-
ber institution. Candidates were initially identified on the
basis of their knowledge of and clinical experience in blood
banking and transfusion medicine. Panel bias was minimized
TABLE 1. Clinical evidence grading system*
Evidence grade Description
Type IObtained from at least one properly designed randomized
controlled trial
Type II-1 Obtained from well-designed controlled trials without
randomization
Type II-2 Obtained from well-designed cohort or case-control
analytic studies, preferably from more
than one center or research group
Type II-3 Obtained from multiple time series with or without the
intervention; dramatic results in uncon-
trolled experiments could also be re-
garded as this type of evidence
Type IIIOpinions of respected authorities, based on clinical ex-
perience, descriptive studies, or reports
of expert committees
Type IV Insufficient to determine role
*  Data taken from Guide to clinical preventive services—an as-
sessment of the effectiveness of 169 interventions.17
TABLE 2. Clinical recommendation grading system*
Recommendation Group consensus Definition
Class I Unanimous or nearly unanimous Conditions for which there is evidence and/or general agreement that
in favor of the recommendation WBC reduction, or the use of WBC-reduced components, is useful
and effective
Class II-a Majority in favor of Conditions for which there is conflicting evidence and/or a divergence
the recommendation of opinion about the usefulness/efficacy of WBC reduction or the
use of WBC-reduced components; the weight of evidence/opinion is
in favor of usefulness/efficacy
Class II-b Majority in favor of Conditions for which there is conflicting evidence and/or a divergence
the recommendation of opinion about the usefulness/efficacy of WBC reduction or the
use of WBC-reduced components; usefulness/efficacy is less well
established by evidence/opinion
Class III Unanimous or nearly unanimous Conditions for which there is evidence and/or general agreement that
against the recommendation WBC reduction or the use of WBC-reduced components is not use-
ful/effective and in some cases may be harmful
* Data taken from Braunwald E, Antman EM, Beasley JW, et al.20
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by eliminating from consideration strong advocates either
for or against ULR. The Expert Panel comprised seven expe-
rienced UHC faculty physicians in hematology, immunology,
pathology, or transfusion medicine who are active in patient
care. Each panelist signed a financial conflict-of-interest state-
ment and a pledge of objectivity before final appointment to
and acceptance of the position. No honorarium or other fi-
nancial compensation was offered to any panelist. The day
before the Expert Panel meeting, all panelists attended a
UHC-sponsored symposium that covered scientific, regula-
tory, supply, and academic medical center issues relevant to
WBC reduction (see Appendix).
The UHC Expert Panel was charged to provide expert
consultation to the UHC Clinical Practice Advancement Cen-
ter Technology Assessment Group in preparing evidence-
based recommendations for the use of WBC reduced cellular
blood components. Draft questions and statements to be ad-
dressed by the UHC Expert Panel and compiled evidence tables
were prepared by two of the authors (TAR and JPC) and pro-
vided to each panelist before the group convened in Oak
Brook, Illinois, in October 2000. Each recommendation rep-
resents the panel’s majority position after consideration of the
evidence available for each potential indication and an open
voice vote. Disagreements were resolved by further discus-
sion and voting until a consensus or majority was achieved.
Content experts who made presentations at the UHC
symposium also attended the Expert Panel meeting for con-
sultation as requested on points of contention with regard
to the evidence or indications for WBC reduced blood (á list
of these persons appears in the Acknowledgements). A UHC
staff person (JPC) cochaired the meeting. All recommenda-
tions were graded according to a modified classification
scheme defined by the American College of Cardiology and
the American Heart Association (Table 2).20
TABLE 3. UHC consensus recommendations for the use of WBC-reduced blood components
Recommendations
Clinical
  WBC-reduced components are indicated
    To decrease the incidence of subsequent refractoriness to platelet
       transfusion caused by HLA alloimmunization in patients requiring
       long-term platelet support
    To provide blood components with reduced risk for CMV transmission
    To prevent FNHTR in patients who have had one or more documented
       FNHTR
    To decrease the incidence of HLA alloimmunization in nonhepatic
       solid-organ transplant candidates
  WBC-reduced components are not indicated
    To prevent reactivation of endogenous viral infections such as CMV
       or HIV
    To guard against general immunomodulatory effects: to decrease the
       incidence of cancer recurrence, to decrease the incidence of post
       operative infections, or to decrease postoperative mortality
    To reduce hospital LOS in transfusion recipients
    To prevent transfusion-associated GVHD or TRALI
    To prevent bacterial sepsis
    To prevent transmission of HTLV-I/II, EBV, HHV-8, or other,
       unknown infectious agents
    To prevent transmission of vCJD or other prion diseases
Administrative
  The use of prestorage methods for WBC reduction is recommended
       for the preparation of RBC and nonapheresis platelet components
       in community blood centers or hospital-based blood banks
  The implementation of ULR for purposes of establishing or maintaining
       a single inventory of RBCs and platelets is not justified from a
       scientific or policy perspective
Policy
  The benefit-to-risk ratio associated with WBC reduction is not sufficient
       to justify requiring the ULR of all non-WBC (RBCs and platelets)
       cellular transfusion components
  The benefit-to-cost ratio associated with WBC reduction is not sufficient
       to justify requiring the ULR of all non-WBC (RBCs and platelets)
       cellular transfusion components
  The implementation of ULR for purposes of ensuring harmony of blood
       policy between the United States and other countries is not justified
       from a scientific or policy perspective
  The FDA should not mandate ULR of the US blood supply on the basis
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THE EXPERT PANEL’S
RECOMMENDATIONS
The UHC Expert Panel developed clinical, administrative, and
policy recommendations for the use of WBC reduced com-
ponents, based on information from several sources: the
published medical literature; the UHC-sponsored sympo-
sium on ULR; and each panelist’s clinical experience. The
UHC recommendations are reviewed here and are summa-
rized in Table 3.
Clinical recommendations for WBC reduced blood
components
Indications are uses that the UHC Expert Panel believes are
supported by published evidence and clinical experience.
Nonindications are uses that the panel believes are not sup-
ported or justified by published clinical evidence or clinical
experience.
Indications for WBC reduced blood components
Indication 1: To decrease the incidence of subsequent re-
fractoriness to platelet transfusion caused by HLA
alloimmunization in patients requiring long-term platelet
support (Class I/Type I).
This unanimous recommendation was based on the
results of eight randomized trials of WBC reduced compo-
nents as a means of reducing HLA alloimmunization and
platelet refractoriness.21-28 The composite data show a clear
trend toward less formation of HLA alloantibodies in recipi-
ents of WBC reduced components than in those of
nonmodified components. However, the panel warned that
clinical extrapolation of these findings to other patient groups
is not justified, for several reasons. First, the subjects in the
published trials were immunosuppressed, by virtue either
of their underlying illness (malignancies) or of the receipt of
cytotoxic therapy, and they required multiple platelet trans-
fusions. Second, the WBC reduction methods used were not
the same in all studies and are significantly different from
those available at present. Third, all but one of the individual
studies were insufficiently powered to provide definitive in-
formation on this topic.28 The UHC Expert Panel therefore
concurred that current clinical evidence does not show that
WBC reduced cellular components would provide clinically
relevant benefits to immunocompetent patients who require
a transfusion under acute circumstances, such as elective
surgery, trauma, or other situations that result in significant
blood loss.
Indication 2: To provide blood components with re-
duced risk for CMV transmission (Class I/Type I).
The Expert Panel concluded by a 6-to-1 vote that cur-
rent WBC reduction methods and manufacturing standards
yield components that may be considered equivalent to CMV-
seronegative components. This recommendation is based on
substantial Type I data that consistently show the nearly to-
tal elimination of CMV transmission via WBC reduced RBCs
and platelets.29-37 It was, however, noted that these results
were obtained primarily in patients who were undergoing
cytotoxic chemotherapy, and thus they may not be appli-
cable to all immunosuppressed individuals. A decision to
order WBC reduced components in lieu of CMV-seronega-
tive blood should be based on the potential susceptibility of
each patient to disseminated CMV infection, as implied by
his or her immune status, underlying comorbidities, and
overall physical condition.38
Indication 3: To prevent a subsequent FNHTR in patients
who have had one documented FNHTR (Class I/Type II-3).
The UHC Expert Panel voted 6 to 1 in favor of this indi-
cation, stressing that this recommendation applies to both
platelet and RBC transfusions. The panelists concurred that
the use of WBC reduced components will not prevent all
FNHTRs, regardless of indication or patient subset. No pub-
lished data are available from randomized trials that by de-
sign examined the potential impact of WBC reduced com-
ponents on the incidence of FNHTR.8
Indication 4: To decrease the incidence of HLA
alloimmunization in nonhepatic solid-organ transplant can-
didates (Class I/Type II-3).
This unanimous recommendation applies to platelet and
RBC transfusions. The panel was not aware of any data from
randomized clinical trials specifically addressing the role of
WBC reduced blood in transplantation outcomes. Several
panelists further noted that heart and kidney transplanta-
tion must be considered different from liver transplantation,
because of differences in HLA presentation and immunore-
activity in those organs. Because significant clinical data
clearly show a lower incidence of transfusion-associated HLA
alloimmunization in patients who receive WBC reduced com-
ponents,28 the panelists believe that WBC reduced compo-
nents could reasonably be expected to be beneficial in
nonhepatic transplant candidates.
Nonindications for WBC reduced blood components
Nonindication 1: To prevent reactivation of endogenous vi-
ral infections such as HIV or CMV (Class III/Type I).
The UHC Expert Panel concluded unanimously that
WBC reduced components do not affect the risk of reactiva-
tion of endogenous viral infection in allogeneic transfusion
recipients, as determined primarily from the results of the
Viral Activation Transfusion Study (VATS).39 The panel was
not aware of any other clinical trials that have directly exam-
ined the possible impact of WBC reduction in this situation.
Nonindication 2: To guard against general immunomodu-
latory effects: to decrease the incidence of cancer recurrence;
to decrease the incidence of postoperative infections; or to
decrease postoperative mortality (Class III/Type I).
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Five published Type I studies40-44 were considered by the
UHC Expert Panel in making this unanimous recommenda-
tion. While some data suggest greater risk for postoperative
infections in patients who receive standard components than
in those who receive WBC reduced components, the effect
of WBC reduced blood on cancer recurrence or postopera-
tive mortality is unclear. Moreover, a host of potentially con-
founding variables makes it difficult to compare results
among the studies. These include, but are not limited to, dif-
ferences in study design (single- vs. multi-center), patient
populations, the methods used to WBC reduce components,
and the residual WBC content of the components that were
actually transfused.10,45,46
Nonindication 3: To reduce length of hospital stay in
transfusion recipients (Class III/Type I).
The UHC Expert Panel was unanimous in this recom-
mendation. Length of stay (LOS) in hospital is a topic of great
interest from the institutional perspective, because of the
potentially significant cost savings or cost avoidance associ-
ated with its reduction. The only published Type I study that
specifically examined this issue showed that the average LOS
for cardiac surgery patients who received WBC reduced
blood was not significantly different from that for patients
who received standard components.44 Clinical trials of WBC
reduced components that incorporate LOS as a primary
endpoint would be of substantial value in shaping public
policy as it relates to ULR.
Nonindication 4: To prevent transfusion-associated
GVHD or transfusion-related acute lung injury (TRALI) (Class
III/Type I).
The UHC Expert Panel concluded unanimously that
WBC-reduced components have no role in preventing trans-
fusion-associated GVHD or TRALI. Transfusion of viable
WBCs may result in GVHD, particularly in immunosup-
pressed individuals.47 Pretransfusion irradiation of blood,
which inhibits the proliferation of donor lymphocytes but
has no significant effect on RBC, platelet, or granulocyte func-
tion, is used routinely to prevent this complication. By con-
trast, TRALI appears to be caused by antibodies or other
soluble substances in donor plasma that react with recipient
granulocytes, leading to increased permeability of the pul-
monary microcirculation.1 Thus, because WBC reduction
procedures do not specifically remove plasmatic solutes from
blood, the use of WBC reduced components would not re-
duce the risk of TRALI.
Nonindication 5: To prevent bacterial sepsis (Class III/
Type III).
Bacterial contamination of cellular components is a rare
event with potential sources that include the blood collec-
tion system, an inadequately cleaned donor skin site, or un-
recognized donor bacteremia. While the true frequency of
transfusion-associated bacterial infection is not known, it
occurs more often with platelets than with RBCs, presum-
ably because of differences in the methods used to prepare
and store these components. Data from in vitro studies show
that prestorage WBC reduction removes bacteria (most
prominently, Yersinia enterocolitica) from contaminated
blood components.7 Because no data are available from
comparative clinical studies of WBC reduction as a means of
reducing transfusion-associated bacterial infection, however,
the UHC Expert Panel concurred unanimously that WBC
reduction is not indicated for this purpose.
Nonindication 6: To prevent transmission of HTLV-I/
II, EBV, human herpesvirus 8 (HHV-8), or other, unknown
infectious agents (Class III/Type IV).
The UHC Expert Panel unanimously held that WBC re-
duced components are not indicated as a means of prevent-
ing the transmission of HTLV-I/II, EBV, HHV-8, or other,
unknown infectious agents. All of these viruses are believed
to be sequestered in WBCs and thus are potentially trans-
missible via RBC and platelet preparations. However, no
clinical data are available from studies in which WBC reduced
components were compared with nonmodified versions as
vectors for infection.8
Nonindication 7: To prevent transmission of vCJD or
other prion diseases (Class III/Type IV).
The UHC Expert Panel unanimously recommended that
WBC reduced blood components are not indicated as a
means of preventing the transmission of vCJD or other prion
diseases. Data from animal studies and case reports suggest
the possibility that CJD may be transmitted by the transfu-
sion of blood or albumin.13 However, no confirmed case of
CJD has been attributed to the transfusion of blood or other
blood derivatives, nor has any cluster of CJD been reported
after the administration of a pooled plasma derivative that
was known to contain units obtained from a donor who sub-
sequently developed CJD.13 Further, because prions are found
in plasma independent of WBCs, WBC reduction by itself may
be ineffective as a preventive measure.
Administrative recommendations
The UHC Expert Panel considered a number of issues that
were categorized as administrative rather than clinical. These
are discussed in the next few paragraphs.
Recommendation 1: The use of prestorage methods for
WBC reduction is recommended for the preparation of RBC
and nonapheresis platelet components in community blood
centers or hospital-based blood banks (Platelets: Class I/Type
II-1; RBCs: Class IIa/Type III).
A number of in vitro studies have shown that WBC-de-
rived proinflammatory cytokines (IL-1, IL-6, and TNFα),
chemokines, complement fragments, histamine, and lipids
accumulate to clinically significant levels in the plasma of
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platelet concentrates (PCs) during storage.48 These have been
postulated to be etiologically involved with a majority (>85%)
of FNHTRs to platelets. A direct role for WBC-derived
bioreactive substances in eliciting transfusion reactions is
supported by the results of a randomized trial in which pa-
tients who received a transfusion of the cytokine-rich plasma
component prepared from standard PCs experienced a sig-
nificantly higher incidence of severe reactions than the same
patients who received reconstituted, cytokine-depleted
platelets from the same unit.49 These investigators further
reported that the concentrations of IL-1β and IL-6 in the
plasma correlated positively with the WBC count in the platelet
component. A subsequent randomized trial demonstrated
that poststorage removal of cytokine-replete plasma from
PCs was more effective than poststorage WBC reduction
using bedside filtration in preventing severe FNHTRs to plate-
lets.50 Together, these results provide sufficient justification
for recommending prestorage WBC reduction as the pre-
ferred means of minimizing FNHTRs in recipients of pooled
random-donor platelets. However, no data from a random-
ized, controlled trial directly demonstrate the clinical effec-
tiveness of prestorage WBC reduction of platelets in the pre-
vention of FNHTR.
In contrast to PCs, RBC concentrates accumulate
bioreactive substances at consistently lower levels, most likely
as a result of their storage at 4°C, and perhaps also of the types
and numbers of WBCs present in the RBC component.50 No
data from randomized trials show a causal relationship be-
tween storage-generated cytokines and acute febrile reactions
to RBCs. Rather, most FNHTRs in RBC recipients appear to
be mediated by a reaction between incompatible donor WBCs
present in the RBC unit and antibodies in the recipient’s
plasma.48 Because WBCs are responsible for RBC-induced
FNHTRs, poststorage or bedside filtration is an effective way
to minimize such reactions.8 However, as it is difficult to en-
sure adequate QC with bedside filtration, the UHC Expert
Panel recommends the use of prestorage WBC reduced RBC
concentrates when WBC reduced cells are indicated.
Recommendation 2: The implementation of ULR for
purposes of establishing or maintaining a single inventory of
RBCs and platelets is not justified from a scientific or policy
perspective (Class II-b/Type IV).
The UHC Expert Panel unanimously recommends that
inventory management considerations should not constitute
an overriding basis for community blood banks or hospitals
to convert to 100-percent use of WBC reduced components.
This issue has not been studied systematically to determine
the impact of a single inventory on operations, safety, or
uniformity in the delivery of blood services. The panelists
believe that inventory management is a local issue that must
remain flexible in the context of prevailing conditions.
Policy recommendations
The UHC Expert Panel considered four issues relevant to na-
tional blood policy and made the following recommendations.
Recommendation 1: The benefit-to-risk ratio associ-
ated with WBC reduction is not sufficient to justify requiring
the ULR of all non-WBC (i.e., RBCs and platelets) cellular
transfusion components.
The UHC Expert Panel voted 5 to 2 that WBC reduced
RBCs and platelets provide significant and necessary clinical
benefits in specific subsets of patients, as recommended in
Table 3. The panel noted a finite (small) risk for an adverse
event, such as red-eye syndrome or a drop in blood pres-
sure, that was associated with the use of WBC reduced com-
ponents in any group of patients regardless of indication,
although this refers particularly to components produced
by bedside filtration. Given the equivalence of risk with the
use of WBC reduced components in all patients, the ben-
efit-to-risk ratio would be expected to become very large
in patients who truly require WBC reduced blood. By con-
trast, because there is no proven clinical benefit associ-
ated with the use of WBC reduced components for indica-
tions other than the four recommended in this assessment,
the numerator of the benefit-to-risk ratio goes to zero in
the nonrecommended scenarios. If the denominator of
the ratio remains the same small number for WBC reduced
components in all patients, this ratio therefore would go
to zero or some exceedingly small number that would
presumably be less than the ratio for patients who truly
benefit from receiving WBC reduced components. Finally,
with respect to the term “universal,” most patients who
require WBC reduced components already receive such
components under current medical practice. Thus, the
panel found that ULR cannot be justified on the basis of
either published clinical evidence or experience.
Several panelists further warned that a federal mandate
for ULR could have a number of unintended, deleterious
consequences secondary to the supply and potency of spe-
cific components. For example, donors who are sickle-cell
trait carriers or who have other conditions that are not ame-
nable to WBC reduction procedures would be excluded from
donation, or their donor units may be wasted in unsuccess-
ful postdonation modification. A counter-argument pro-
posed in favor of mandated ULR is that it would ensure that
all patients for whom WBC reduced cellular components are
indicated would receive them.
Recommendation 2: The benefit-to-cost ratio associ-
ated with WBC reduction is not sufficient to justify requiring
the ULR of all non-WBC (i.e., RBCs and platelets) cellular
transfusion components.
The UHC Expert Panel unanimously concluded that the
benefit-to-cost ratio associated with WBC reduction is not
RATKO ET AL.
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sufficient to justify mandating ULR in the US blood system.
No data from controlled trials are available to resolve this
issue in terms of hospital costs, LOS, other costs of treat-
ment, or cost avoidance due to fewer transfusion-related
adverse events in patients who receive WBC reduced com-
ponents, as compared with those factors in patients given
standard units.5,8
The panel strongly believes that, while the US blood sup-
ply itself is as safe as possible with current technology, the
system for delivering transfusion services is at risk. An FDA
mandate for ULR without adequate reimbursement through
the existing inpatient DRG system will result in a direct im-
pact of the increased costs on the institutional blood banks’
budgets. Historically, the unreimbursed costs of mandated
ULR will be accommodated through staff reductions and
cutbacks that will undoubtedly increase the chances for er-
ror and thereby raise the risks of transfusion-related mor-
bidity and mortality. Diversion of these health care resources
into ULR thus could pose a greater threat to all patients than
that posed by non-WBC reduced blood in most patients. The
panel also was unanimous in its belief that it is inappropriate
and nonproductive to discuss the premise of ULR in the
absence of cost considerations, given the delicate financial
situations of a great many US hospitals.
Recommendation 3: The implementation of ULR for
purposes of ensuring harmony of blood policy between the
United States and other countries is not justified from a sci-
entific or policy perspective.
This unanimous recommendation was not based in sci-
ence but instead was deemed a policy issue related to US
leadership in medical science and health care. With the pos-
sible exception of overseas commercial marketing of blood
and blood components, there is no reason for the United
States to adopt ULR to harmonize with the policies of other
countries. The UHC Expert Panel strongly believes that the
United States should continue to exercise leadership in sci-
ence and medical technology, with evidence-based decision
making at the core of its health care system.
Recommendation 4: The FDA should not mandate ULR
of the US blood supply on the basis of current scientific and
medical evidence.
The UHC Expert Panel concurred that FDA action is ap-
propriate and necessary to protect the public health in the face
of an acute threat, as starkly exemplified by the discovery of
HIV in donated blood more than 20 years ago. However, the
panel was unanimous in its belief that allogeneic passenger
WBCs do not pose a significant clinical risk to the vast major-
ity of patients who require component transfusions under
acute circumstances. Therefore, the FDA should not imple-
ment mandatory ULR. Selective use of WBC reduced compo-
nents as indicated remains the preferred approach. The panel
also warned that, should ULR become a manufacturing re-
quirement in the United States, further clinical research in this
area will likely become difficult, if not impossible, to justify
from an ethical and financial perspective.
CONCLUSION
Blood is an indispensable component of the modern health
care armamentarium that can be viewed dichotomously.
From one perspective, blood is a life-sustaining clinical asset
that provides well-known clinical benefits to patients who
require a transfusion. By contrast, although the US blood sup-
ply has never been safer, allogeneic transfusion still entails a
plethora of potential risks, a number of which are associated
with significant morbidity and mortality.1,51 Transfusion-
transmitted infections are well documented, especially HIV,
HBV, and HCV, as well as pathogenic bacteria.1,52 Overall, the
risks for transfusion-related infections are relatively low, and
they appear to be declining in the US blood supply.53 Despite
this decline, however, blood safety remains a subject of con-
cern to many patients and to some physicians.54-56
The UHC Expert Panel concurred that WBC reduced
RBCs and platelets provide significant, real, and necessary
clinical benefits in selected subsets of patients, who already
receive such components under current medical practice.
By contrast, the panel firmly believes that current clinical evi-
dence is insufficient to demonstrate that the use of WBC re-
duced components in patients outside these specific groups
provides significant, clinically relevant benefits that are not
obtained with non-WBC reduced components. Given this
position, the panel indicated substantial concern that an
unfunded mandate for ULR would have a number of unin-
tended, deleterious consequences secondary to the supply
and potency of specific components, such as those from
persons who are sickle-cell trait carriers or who have other
conditions that are not amenable to WBC reduction proce-
dures or are in short supply, such as rare phenotypes. They
further suggested that the current lack of an adequate reim-
bursement mechanism through the existing inpatient DRG
system will result in a direct impact of the increased cost on
the hospitals’ blood bank budget. On the basis of their expe-
rience, the members of the panel are concerned that the
added costs of mandated ULR will be accommodated
through staff reductions and cutbacks that will increase the
chances for systemic clerical errors. This will thereby raise
the risk of transfusion-related morbidity and mortality for
all blood recipients. Finally, the panel unanimously believes
that it is inappropriate and nonproductive to discuss the
premise of ULR in the absence of cost considerations, given
the beleaguered financial situations of a great number of US
academic medical centers.
The UHC consensus recommendations for the use of
WBC reduced cellular blood components represent an ob-
jective synthesis of the latest scientific and clinical evidence,
in the context of substantial practical experience. They are,
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of course, subject to interpretation and modification to re-
flect local variations in medical standards of practice, the in-
dividualization of patient care, physician experience, patient
demographics, or institutional policies and procedures. It is
imperative, however, that all of the participants involved in
the US health care enterprise—in particular, the blood safety
and regulatory agencies, the blood supply organizations, the
institutional decisionmakers, and individual practitioners—
keep in mind that medical science is dynamic and continu-
ously evolving. It often is not definitive, and its findings fre-
quently are not generally applicable in practice. The corollary
follows that clinical guidelines, recommendations, or regu-
lations, however limited or broad-based in scope, should re-
flect a consensus that considers the available evidence within
the context of the realities of the modern US health care
delivery system.
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APPENDIX 1. INVITED SPEAKERS FOR
THE UHC SYMPOSIUM ON ULR
WBC Reduction of Cellular Blood Components:
Scientific, Clinical, and Economic Issues
Ronald Strauss, MD, University of Iowa Hospitals and
Clinics—Selective versus Universal Leukocyte Reduction: A
Quandary of Scientific/Political/Economic Decisions
Terry Gernsheimer, MD, University of Washington Medi-
cal Center—Leuko  reduction and HIV: The Results of the
VATS Trial
Eleftherios Vamvakas, MD, PhD, New York University
Medical Center—Transfusion-Associated Immunomodulation:
Is it Time for Universal White Cell Reduction?
Walter Dzik, MD, Massachusetts General Hospital—Does
Leuko reduction Shorten Hospital Length of Stay?
Steven Kleinman, MD, University of British Columbia—
Leuko reduction and Variant CJD: Formulating Policy in the
Absence of Data
James AuBuchon, MD, Dartmouth-Hitchcock Medical
Center—Economic Implications of Universal Leuko reduction
WBC Reduction of Cellular Blood Components:
Regulatory and Supply Issues
Linda Chambers, MD, American Red Cross—The Ameri-
can Red Cross as an Advocate for Universal and Prestorage
Leuko reduction
Jong-Hoon Lee, MD, Blood and Plasma Branch, Center for
Biologics Evaluation and Research, FDA—Leukocyte Reduc-
tion: FDA’s Current Thinking
Stephen Nightingale, MD, Office of Public Health and Sci-
ence, DHHS—Leukocyte Reduction: U.S. DHHS Perspective
WBC Reduction of Cellular Blood Components in
Academic Medical Centers
Harold Oberman, MD, University of Michigan Medical
Center—Leukocyte Reduction at the University of Michigan
Medical Center
Mark Brecher, MD, University of North Carolina at
Chapel Hill—Universal Leuko reduction at The University of
North Carolina: Why We Switched
Lawrence Petz, MD, UCLA Medical Center—Universal
Leukocyte Reduction as Seen From the Perspective of Hospi-
tal-Based Physicians
Edward Snyder, MD, Yale-New Haven Hospital—Univer-
sal Leuko reduction: Ivory Tower or Better Medical Care?
Leo McCarthy, MD, Indiana University Medical Center—
Leuko reduction at Clarian Health: Impact on Transfusion Re-
actions and Implications for a Large Transfusion Service
Lawrence Goodnough, MD, Washington University Medi-
cal School—Leuko reduction at Barnes-Jewish Hospital
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